Cellid Co. Ltd - Asset Resilience Ratio

Latest as of September 2025: 11.66%

Cellid Co. Ltd (299660) has an Asset Resilience Ratio of 11.66% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Cellid Co. Ltd debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

₩13.12 Billion

≈ $8.89 Million USD Cash + Short-term Investments

Total Assets

₩112.51 Billion

≈ $76.24 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Cellid Co. Ltd's Asset Resilience Ratio has changed over time. See Cellid Co. Ltd (299660) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Cellid Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Cellid Co. Ltd market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩13.12 Billion	11.66%
Total Liquid Assets	₩13.12 Billion	11.66%

Asset Resilience Insights

Moderate Liquidity: Cellid Co. Ltd has 11.66% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Cellid Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Cellid Co. Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Fortress Biotech Inc NASDAQ:FBIO	Biotechnology	11.59%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Apellis Pharmaceuticals Inc NASDAQ:APLS	Biotechnology	0.58%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
BioArctic AB (publ) ST:BIOA-B	Biotechnology	72.35%
Chengzhi Shareholding Co Ltd SHE:000990	Biotechnology	6.73%

Annual Asset Resilience Ratio for Cellid Co. Ltd (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Cellid Co. Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	11.91%	₩9.06 Billion ≈ $6.14 Million	₩76.09 Billion ≈ $51.56 Million	-11.59pp
2023-12-31	23.50%	₩15.02 Billion ≈ $10.18 Million	₩63.92 Billion ≈ $43.32 Million	-17.24pp
2022-12-31	40.74%	₩18.68 Billion ≈ $12.66 Million	₩45.86 Billion ≈ $31.08 Million	+6.52pp
2021-12-31	34.23%	₩19.94 Billion ≈ $13.51 Million	₩58.26 Billion ≈ $39.48 Million	+9.79pp
2020-12-31	24.43%	₩12.07 Billion ≈ $8.18 Million	₩49.40 Billion ≈ $33.48 Million	+21.38pp
2019-12-31	3.05%	₩1.60 Billion ≈ $1.08 Million	₩52.52 Billion ≈ $35.59 Million	-52.42pp
2018-12-31	55.47%	₩7.89 Billion ≈ $5.34 Million	₩14.22 Billion ≈ $9.63 Million	-35.40pp
2017-12-31	90.86%	₩4.51 Billion ≈ $3.06 Million	₩4.96 Billion ≈ $3.36 Million	+4.43pp
2016-12-31	86.44%	₩3.29 Billion ≈ $2.23 Million	₩3.81 Billion ≈ $2.58 Million	--

pp = percentage points

About Cellid Co. Ltd

KQ:299660 Korea Biotechnology

Market Cap

$63.58 Million

₩93.82 Billion KRW

Market Cap Rank

#20952 Global

#1292 in Korea

Share Price

₩3180.00

Change (1 day)

-1.55%

52-Week Range

₩2315.00 - ₩8890.00

All Time High

₩127128.20